Opdivo plus chemo improves event-free survival in NSCLC patients
Detailed results from the CheckMate-816 trial will be shared at an upcoming medical conference
Read Moreby Lucy Parsons | Nov 8, 2021 | News | 0
Detailed results from the CheckMate-816 trial will be shared at an upcoming medical conference
Read Moreby Lucy Parsons | Oct 13, 2021 | News | 0
Conditional marketing authorisation granted for patients with advanced NSCLC with METex14 skipping alterations
Read Moreby Lucy Parsons | Oct 12, 2021 | News | 0
Phase Ib CodeBreaK study evaluated Lumakras in over ten different investigational combination regimens
Read Moreby Lucy Parsons | Sep 22, 2021 | News | 0
Agreement will evaluate Verastem’s dual RAF/MEK inhibitor with Amgen’s KRAS G12C inhibitor
Read Moreby Lucy Parsons | Sep 20, 2021 | News | 0
Positive data presented at the 2021 ESMO virtual congress
Read Moreby Lucy Parsons | Sep 10, 2021 | News | 0
Project Orbis is an international collaborative programme between the FDA and worldwide regulatory agencies
Read Moreby Lucy Parsons | Jul 15, 2021 | News | 0
The positive opinion has been issued via the MHRA’s early access the medicine (EAMS) scheme
Read Moreby Lucy Parsons | May 24, 2021 | News | 0
First targeted treatment authorised in the US for NSCLC patients with EGFR exon 20 insertion mutations
Read Moreby Selina McKee | May 7, 2021 | News | 0
The POSEIDON trial is the first Phase III study to demonstrate an overall survival benefit with tremelimumab
Read Moreby Selina McKee | May 7, 2021 | News | 0
Decision brings the innovative treatment to early-stage lung cancer patients, helping to address unmet need in this setting
Read Moreby Lucy Parsons | May 5, 2021 | News | 0
Checkpoint inhibitor specifically approved for patients with high PD-L1 expression
Read Moreby Selina McKee | Apr 9, 2021 | News | 0
The combination is not considered to be a cost-effective use of NHS resources in this setting
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479